TherapeuticsMD (TXMD) Accumulated Expenses (2011 - 2026)

TherapeuticsMD (TXMD) has reported Accumulated Expenses for 16 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 17.99% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 million (up 17.99% YoY), and the FY2025 full-year result was $1.7 million, down 18.15% from the prior year.
• Accumulated Expenses retreated to $1.9 million in Q2 2026 per TXMD's latest filing, from $2.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $18.8 million in Q4 2022 and bottomed at $1.6 million in Q2 2025.
• Historically, Accumulated Expenses has averaged $3.6 million across 5 years, with a median of $2.2 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses slumped 83.38% in 2023, then increased 25.22% in 2026.
• Over 5 years, Accumulated Expenses stood at $18.8 million in 2022, then plunged by 83.38% to $3.1 million in 2023, then tumbled by 32.11% to $2.1 million in 2024, then fell by 18.15% to $1.7 million in 2025, then increased by 7.75% to $1.9 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.9 million, $2.2 million, and $1.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.